Synthetic Biologics Inc (NYSE MKT:SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported the initiation …
Synthetic Biologics Inc (NYSE MKT:SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, dosed the first participant …
In a research report published today, H.C.
In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Synthetic Biologics (NYSE:SYN) with a $6 price target, after the company held an R&D day on …
In a research note released yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Synthetic Biologics (NYSE:SYN) with a $6 price target …
In a research report published August 14, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Synthetic Biologics (SYN) with a $6 price target, following the company’s second-quarter results, burning …
In a research report published Friday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Synthetic Biologics (SYN) with a $6 price target, which …